Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring AML, allogeneic transplantation, high-risk, karyotype
Eligibility Criteria
Inclusion Criteria: newly-diagnosed AML either poor risk cytogenetics and/or bad response to the first cycle of IC defined by more than 10% marrow blasts on day 15 HLA-compatible donor (maximum one HLA-antigen mismatch) Exclusion Criteria: no donor Age < 16 years > 75 years Cardiac insufficiency requiring treatment or symptomatic coronary artery disease Hepatic disease, with AST > 2 times normal Severe hypoxemia , pO2 < 70 mm Hg, with decreased DLCO < 70% of predicted; or mild hypoxemia, pO2 < 80 mm Hg with severely decreased DLCO < 60% of predicted Impaired renal function (creatinine > 2 times normal or creatinine clearance < 50% for age, weight, height) HIV-positive patients due to risk of reactivation or acceleration of HIV replication Female patients who are pregnant or breast feeding due to risks to fetus from conditioning regimen and potential risks to nursing infants Life expectancy severely limited by diseases other than malignancy
Sites / Locations
- University hospital Carl Gustav Carus